Contribution: Industrial Research Assistance Program – Contributions to Firms
Symvivo Corporation
$3,071,774.00
COVID-19 Response (VI): STAGE 2 Oral DNA Vaccine Development
FY 2021-22 · 2021-06-01
Summary
This project will involve further development and characterization of oral bacTRL-based vaccines. This work includes the preclinical development of additional bacTRL-based products including emergent or predicted SARS-CoV-2 variants, as well as the continued evaluation of the lead vaccine candidate in a Phase I clinical trial.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Burnaby|Burnaby, British Columbia, Canada
Recipient Type
For-profit organization
Business Number
818996241
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2021-06-01 | 2021-22 | $4,571,774.00 |
| 1 | 2021-06-01 | 2021-22 | $4,571,774.00 |
| 2 | 2021-06-01 | 2021-22 | $4,571,774.00 |
| 3 | 2021-06-01 | 2021-22 | $3,071,774.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The total amended value is -1,500,000 dollars.
Additional Information (French)
Cet accord a été modifié 1 fois La valeur totale des modifications est de -1 500 000 dollars.
Agreement End Date
2023-03-31
Agreement Number
974484
Agreement Start Date
2021-06-01
Agreement Title
COVID-19 Response (VI): STAGE 2 Oral DNA Vaccine Development
Agreement Title (French)
Réponse face à la COVID-19 (VI) : Développement d'un vaccin oral à ADN de stade 2
Agreement Type
Contribution
Agreement Value
$3,071,774.00
Amendment Date
2023-01-28
Amendment Number
3
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
This project will involve further development and characterization of oral bacTRL-based vaccines. This work includes the preclinical development of additional bacTRL-based products including emergent or predicted SARS-CoV-2 variants, as well as the continued evaluation of the lead vaccine candidate in a Phase I clinical trial.
Description (French)
Ce projet prévoit la poursuite du développement et de la caractérisation de vaccins oraux à base de bacTRL. Ce travail comprend la mise au point préclinique de produits supplémentaires à base de bacTRL, y compris les variants émergents ou prévus du SRAS-CoV-2, ainsi que la poursuite de l'évaluation du principal vaccin candidat dans le cadre d'un essai clinique de phase 1.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Burnaby South
Federal Riding (French)
Burnaby-Sud
Federal Riding Number
59003
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
818996241
Recipient City
Burnaby|Burnaby
Recipient Country
CA
Recipient Legal Name
Symvivo Corporation
Recipient Operating Name
Alexander Graves
Recipient Postal Code
V5J 5J8
Recipient Province or Territory
BC
Recipient Type
F
Reference Number
172-2021-2022-Q1-974484
